Date: Apr 23, 2014 Source: Company Data (
click here to go to the source)
Ferndale, Michigan based 21st Century Therapeutics, Inc. (21CTI) signed an agreement with a Chinese technology company, Beijing WecareS Biopharmaceutical Co. Ltd., to provide enzyme immobilization services in the United States. "This collaboration will help us expand our technology into enzyme business, broaden our areas of expertise, and help generate some short-term revenues", said Dr. Frederick Valeriote, CEO of 21CTI.
According to 21CTI's President, Dr. JJ Shaw, current global market for industrial enzymes is more than $5 billion/year. However, most enzymes were not recovered because of the additional procedure and cost to recover. Our enzyme immobilization technology makes it easy to recover and reuse the enzyme, more cost effective and environmentally friendly. Using our novel technology, enzyme molecules are enclosed (thus immobilized) in porous molecular cages, which are insoluble particles (diameter around 50-500 μm), and the immobilized enzyme can be used many times and still maintains its high activity.
21CTI is a private pharmaceutical discovery and development company, specializing in cancer and immunemediated diseases. In addition, 21CTI is also involved in other closely related biotechnologies such as enzyme immobilization.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchanges rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. 21CTI's management does not undertake any responsibility to update the forward-looking statements contained in this release.
Contact: Frederick Valeriote (586) 863-8298 or JJ Shaw (734) 330-6052
Website: www.21-cti.com
e-mail: jshaw@21-cti.com
